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ABSTRACT
Neuroendocrine tumors (NETs) metastasize to the skeleton in approximately 20% 
of patients. We have previously shown that the epithelial-mesenchymal transition 
(EMT) regulates the NET osteotropism and that CXCR4 overexpression predicts bone 
spreading. Here, we unravel the molecular mechanisms linking the activation of the 
CXCL12/CXCR4 axis to the bone colonization of NETs using cell lines representative 
of pancreatic (BON1, CM, QGP1), intestinal (CNDT 2.5), and bronchial origin (H727). 
By combining flow cytometry and ELISA, BON1, CM and QGP1 cells were defined as 
CXCR4high/CXCL12low, while H727 and CNDT 2.5 were CXCR4low/CXCL12high. CXCL12 
was inert on cell proliferation, but significantly increased the in vitro osteotropism of 
CXCR4high/CXCL12low cells, as assessed by transwell assays with or without Matrigel 
membranes. In these cells, CXCL12 induced in vitro a marked EMT-like transcriptional 
shift with acquirement of a mesenchymal shape. The nuclei of CXCR4high/CXCL12low 
NET cells were typically enriched in non-phosphorylated CXCR4, particularly upon 
agonist stimulation. Silencing of CXCR4 via siRNA prevented the CXCL12-induced EMT 
in CXCR4high/CXCL12low NET cell lines resulting in the abrogation of both migration and 
transcriptional mesenchymal patterns. Our data suggest that CXCL12 conveys EMT-
promoting signals in NET cells through CXCR4, which in turn regulates transcriptional, 
morphologic and functional modifications resulting in enhanced in vitro osteotropism 
of NET cells. Unique functions of CXCR4 may be segregated in relation to its subcellular 
localization and may acquire potential relevance in future in vivo studies.
INTRODUCTION
Neuroendocrine tumors (NETs) are heterogeneous 
malignancies arising from the diffuse neuroendocrine 
system. They are characterized by a relatively indolent 
rate of growth and share the ability to produce a variety 
of peptide hormones and vasoactive amines. Although 
NETs may develop in almost all organs, they are prevalent 
within the lung, the pancreas and the gastrointestinal tract, 
and their incidence has markedly increased over the last 
three decades [1, 2]. Up to 20% of patients with NETs 
are diagnosed with bone metastases, whose incidence and 
negative influence on both tumor morbidity and patient 
prognosis have been recently reported by our group as 
well as by others [3–5]. In relation to the natural history of 
NETs, the detection of bone involvement within 3 months 
from the primary NET diagnosis is apparently associated 
with a very dismal survival of only 12 months, and such 
a poor clinical outcome may be the epiphenomenon of an 
underlying peculiarly aggressive disease [3].
We have previously demonstrated that the epithelial-
mesenchymal transition (EMT), a transdifferentiation 
program that promotes changes of the cell state conferring 
mesenchymal plasticity to epithelial cells [6], is 
overactive in bone-colonizing NETs [3]. In this context, 
overexpression of C-X-C chemokine receptor type 4 
(CXCR4) in primary tumors appeared highly predictive 
of skeletal metastases. Both CXCR4 and its ligand C-X-C 
motif chemokine 12 (CXCL12) act as positive regulators 
of the invasion-metastasis cascade, and their pro-tumor 
effects have been attributed to i) autocrine mechanisms 
promoting both proliferation and angiogenesis; and ii) 
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paracrine mechanisms leading to the recruitment of 
CXCR4+ cancer/immune/stromal cells to CXCL12-
overexpressing organs (i.e., bone, liver and lung), resulting 
in the formation of the so-called pre-metastatic niche [7, 8].
In NETs, the functional role of the CXCL12/
CXCR4 synapse has been scantily investigated. As 
compared with normal tissue, both CXCL12 and CXCR4 
are overexpressed in NETs, where they signal through the 
mTOR pathway reinforcing the uncontrolled cell growth 
[9]. Amongst lung, pancreatic and ileal NETs, increased 
levels of CXCR4 seem to correlate with higher tumor 
malignancy and are associated with poor patient outcomes 
[10–12]. Global gene expression profiling of GOT1 ileal 
carcinoid cells revealed a marked upregulation of CXCR4 
in response to hypoxia, and the agonist stimulation of 
CXCR4 was able to activate the mitogen-activated protein 
kinase (MAPK) p42/44 pathway, resulting in increased 
tumor cell migration [13].
How NET cells acquire the ability to metastasize 
and how organ-specific metastatic traits arise in primary 
tumors are still unanswered questions. This study was 
aimed at investigating the functional role of the CXCL12/
CXCR4 axis in modulating the bone tropism of NETs in 
in vitro experimental models, and depicts potential future 
applications for NET treatment by inhibiting the CXCR4-
driven EMT as a crucial step of the metastatic process.
RESULTS
CXCR4 and CXCL12 are differentially 
expressed in NET cell lines 
By flow cytometry, surface levels of CXCR4 
measured by mean fluorescence intensity (MFI) ratio were 
significantly higher in pancreatic NET cell lines (BON1, 
CM, QGP1) as compared with H727 and CNDT 2.5 cells 
(p = 0.01; Table 1). Membrane expression of CXCR4 
occurred in > 25% of BON1 and QGP1 cells, whereas lower 
values were detected in CM, H727 and CNDT 2.5 cells. 
Following Bonferroni’s post-test, the rate of expression of 
CXCR4 was significantly higher in BON1 and QGP1 cell 
lines only when compared with CNDT 2.5 cells (p < 0.01). 
Lymphocytes used as positive control showed a MFI ratio of 
1.19, with 45% of positive cells. CXCL12 secretion by NET 
cells is summarized in Table 1, that shows how cell lines 
expressing low levels of surface CXCR4, namely H727 and 
CNDT 2.5, produced significantly higher amounts of the 
cytokine (p = 0.04). Based on these findings, we indicated 
BON1, CM and QGP1 as CXCR4high/CXCL12low cell 
lines, whereas H727 and CNDT 2.5 cells were classified as 
CXCR4low/CXCL12high.
CXCL12 is inert on NET cell proliferation 
CXCL12 up to 100 ng/ml was tested by MTS assay. 
No significant effect was observed even after 72 hrs of 
incubation, irrespective of the concentration of CXCL12. 
The time-dependent response of NET cells to 100 ng/ml of 
CXCL12 is depicted in Supplementary Figure 1.
The in vitro osteotropism of NET cell lines is 
influenced by CXCL12 
The effect of CXCL12 on both the migratory and 
invasive potential of NET cell lines was assessed by 
transwell assays. As represented in Figure 1A, NET cells 
showed similarly low migration towards the FCS-deprived 
medium (p > 0.05). Only BON1 cells significantly 
migrated in the presence of bone fragments (p < 0.0001), 
thus implying intrinsic osteotropism. This constitutive 
activity remained unchanged after CXCL12 pretreatment 
which, however, significantly improved the migration 
of CM and QGP1 cells towards the bone-conditioned 
medium (p = 0.02 and p = 0.03, respectively). On the 
contrary, both H727 and CNDT 2.5 cell lines failed to 
show osteotropism in vitro, and their migratory capability 
was not influenced by pre-conditioning with CXCL12.
We then used matrigel-coated transwell inserts to 
evaluate the invasive potential of NET cells (Figure 1B). 
Invasiveness of CM and QGP1 cell lines was natively 
higher than BON1 cells (p = 0.002) and exposure to the 
bone-conditioned medium further increased this activity in 
both BON1 and QGP1 cell lines (p = 0.04 and p = 0.03, 
respectively). Furthermore, pretreatment with CXCL12 
enhanced the invasive potential of BON1 and CM cells 
(p = 0.004 and p = 0.04, respectively), while leading 
to a borderline increase in QGP1 cells (p = 0.07). As in 
migration experiments, H727 and CNDT 2.5 cell lines 
did not show any significant bone tropism, even after 
pretreatment with CXCL12. Taken together, these data 
indicate that the CXCR4high/CXCL12low BON1, CM and 
QGP1 cell lines express variable levels of osteotropism 
in vitro, which is further increased by CXCR4 stimulation. 
On the contrary, both H727 and CNDT 2.5 cell lines, as 
models of CXCR4low/CXCL12high cells, appear defective 
in intrinsic osteotropism and are insensitive to CXCL12.
CXCL12 drives EMT in CXCR4high/CXCL12low 
NET cells 
Since CXCL12 influenced the migration and 
invasiveness of several NET cell lines, we verified its 
potential in eliciting the transcriptional machinery driving 
EMT. To this aim, we screened by RT-PCR 12 EMT-
related genes in NET cell lines at baseline as well as after 2 
or 24 hr-treatment with CXCL12 or TGF-β1. As depicted 
in Figure 2, NET cell lines constitutively differed in EMT 
gene expression. BON1 cells, indeed, showed significantly 
higher mRNA of CXCR4 (p = 0.04), CTGF (p < 0.001), 
SNAIL (p < 0.001) and IL-11 (p < 0.001), in parallel with 
the lowest expression of TGF-β1 (p < 0.0001). RANK 
was significantly upregulated in BON1 and QGP1 cells 
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Table 1: CXCR4 and CXCL12 measurement in NET cell lines
CXCR4 surface expression CXCL12 secretion
MFI ratio 
(mean ± SE)
p* % of positive 
cells (mean ± SE)
p* pg/ml 
(mean ± SE)
p*
Cell lines 0.01 < 0.01 0.04
BON1 2.78 ± 0.32 26.8 ± 2.7 12.2 ± 1
CM 3.51 ± 0.84 11.2 ± 4.5 18.7 ± 0.6
QGP1 2.35 ± 0.42 26.3 ± 5.3 5.5 ± 0.7
H727 1.07 ± 0.19 14 ± 2.3 154 ± 54.1
CNDT 2.5 1.58 ± 0.46 7 ± 1.3 200.7 ± 137.3
*One-way ANOVA.
Figure 1: CXCL12 modulates the in vitro osteotropism of CXCR4high/CXCL12low NET cell lines. (A) The migratory potential 
of NET cells was measured by transwell assays. When exposed to the bone-conditioned medium, only BON1 cells significantly enhanced 
their migratory properties as compared with control preparations. After 2 hours of incubation with CXCL12 at 100 ng/ml, both CM and 
QGP1 cell lines acquired significant migratory ability towards the bone. By contrast, CXCR4low/CXCL12high H727 and CNDT 2.5 cell 
lines were not significantly chemoattracted to the bone, even following CXCL12 treatment. (B) Exposure to bone fragments significantly 
increased the invasive potential of both BON1 and QGP1 cell lines, as determined by Matrigel assay. Invasiveness of the CXCR4high/
CXCL12low cell lines was further enhanced by CXCL12 pretreatment. Data are expressed as mean ± SD, and were calculated on at least 
three different experiments. Statistical significance is indicated by *(p < 0.05), or **(p < 0.01).
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as compared with the other cell lines (p < 0.0001). On the 
other hand, PTHrP was minimally expressed in CM cells 
while virtually absent in the other cells (p < 0.001). There 
was no difference in the expression of MMP13, while 
MMP9 mRNA was significantly higher in BON1, QGP1 
and H727 cells with respect to CM and CNDT 2.5 cells. 
The E-cadherin encoding gene CDH1 was overexpressed 
in QGP1, H727 and CNDT 2.5 cell lines rather than in 
BON1 and CM cells (p < 0.001), whereas no difference 
was observed in mRNA levels of CDH2. Finally, EpCAM 
as marker of epithelial differentiation was dramatically 
increased in H727 and CNDT 2.5 cells as compared 
with the three pNET cell lines (p = 0.0007). Overall, at 
baseline, epithelial features were prevalent in CXCR4low/
CXCL12high cell lines, whereas a more mesenchymal 
phenotype was observed in CXCR4high/CXCL12low NET 
cell lines, particularly in BON1 cells.
Changes in mRNA transcription following 2 or 
24 hr-treatment with CXCL12 are summarized in Figure 
3A and Supplementary Figure 2A respectively. Stimulation 
of CXCR4 induced a complete cadherin switch in CM 
and QGP1 cell lines, whereas in BON1 cells upregulated 
CDH2 with no effects on CDH1 mRNA levels. Expression 
of SNAIL was also significantly increased in both BON1, 
CM and QGP1 cells after CXCL12 treatment. A similar 
upregulation was noted for CXCR4 and IL-11 in CM 
and QGP1 cell lines. MMP9 and MMP13 mRNAs were 
significantly augmented by CXCL12 in BON1 cells, and 
in both BON1 and QGP1 cells, respectively. In CNDT 
2.5 cells, CXCL12 reduced the CTGF expression. The 
transcriptional modifications promoted by CXCL12 in 
NET cell lines were similar to those caused by TGF-β1, 
used as positive modulator of EMT [6, 14, 15] (Figure 3B). 
In particular, changes in the mRNA levels of CDH2, 
Figure 2: NET cell lines differ in their baseline EMT-related transcriptional profile. The EMT-related transcriptional profile 
of NET cell lines was explored by RT-PCR. The transcriptional signature of partial EMT was more pronounced in BON1 cells, but was 
also present in CM and QGP1 cell lines. H727 and CNDT 2.5 cells showed prevalent epithelial features (i.e., EpCAM upregulation). Data 
are expressed as 2–Δct, using β-actin as housekeeping gene. Mean values ± SD are represented, and significant differences are marked by 
*(p < 0.05), or **(p < 0.01).
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SNAIL, IL-11, MMP9 and MMP13 were comparable 
in either CXCL12- or TGF-β1-treated cells. Of note, 
downregulation of CDH1 as crucial event in EMT was 
more pronounced after CXCL12 rather than TGF-β1 
treatment. The transcription of TGF-β1, RANK, PTHrP, 
and EpCAM was neither affected by CXCL12, nor by 
TGF-β1 (Supplementary Figure 3). Overall, the changes 
seen after a 2 hr-incubation with CXCL12 or TGF-β1 
persisted even after treatment for 24 hr (Supplementary 
Figure 2). Taken together, these data demonstrate that 
both CXCL12 and TGF-β1 are able to induce an EMT-like 
transcriptional shift in NET cell lines. However, while the 
effects of TGF-β1 treatment were visible in all cell lines, 
only CXCR4high/CXCL12low NET cells were influenced by 
CXCL12 in their transcriptional profile.
CXCR4high/CXCL12low NET cell lines acquire a 
mesenchymal phenotype in response to CXCL12 
We investigated the effects of CXCL12 on the shape 
of NET cells. As depicted in Figure 4A and 4D, before 
treatment both CXCR4high/CXCL12low and CXCR4low/
CXCL12high NET cell lines displayed a polygonal or round 
morphology with an high nuclear-to-cytoplasmic ratio and 
features of anaplasia. After treatment with CXCL12, an 
increased proportion of spindle shaped cells was detected 
in BON1, CM and QGP1 cell lines (Figure 4B), but not 
for H727 and CNDT 2.5 cell lines (Figure 4E). Notably, 
cytoplasmic pseudopodia were particularly evident in 
both CM and QGP1 cell lines (Figure 4H). These shape 
variations appeared similar to those induced by TGF-β1 
in both CXCR4high/CXCL12low and CXCR4low/CXCL12high 
cells (Figure 4C, 4F). As shown in Figure 4J, in BON1, 
CM and QGP1 cells the spindle index [16] significantly 
increased following CXCL12 treatment (p = 0.04, 
p < 0.0001 and p < 0.0001, respectively). Similar effects 
were seen after TGF-β1 treatment.
CXCR4 accumulates within the nuclei of 
CXCR4high/CXCL12low NET cells undergoing 
EMT 
We have previously reported a positive 
nuclear staining in FFPE NET samples subjected to 
Figure 3: CXCL12 and TGF-β1 activate EMT in CXCR4high/CXCL12low NET cell lines. (A) Incubation for 2 hours with 
CXCL12 at 100 ng/ml variably altered the EMT transcriptional profile of CXCR4high/CXCL12low NET cell lines, leading to cadherin 
switch and SNAIL upregulation. Such EMT profile was particularly marked in CM and QGP1 cells, whereas CXCL12 failed to induce 
significant effects on CXCR4low/CXCL12high NET cell lines. (B) TGF-β1 induced EMT-related genes in both CXCR4high/CXCL12low and 
CXCR4low/CXCL12high NET cell lines. Transcript level modifications after cytokine treatment are expressed by 2–ΔΔCT method using β-actin 
as housekeeping gene. Data are presented as mean ± SD. Statistical significance is marked by red lines.
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immunohistochemistry (IHC) using a polyclonal Ab against 
CXCR4 [3]. When investigated by ICC with the same Ab, 
all NET cell lines showed the nuclear localization of the 
receptor in the presence of a weak membranous labeling, 
as represented for CM cells in Figure 5A. As shown in 
Figure 5B, additional ICC experiments employing the 
mAb UMB-2, which specifically binds CXCR4 when 
its C-terminal epitope is non-phosphorylated as result 
of ligand stimulation, revealed a diffuse membranous 
and cytoplasmic staining, in the presence also of nuclear 
immunoreactivity. By confocal microscopy, the UMB-2 
mAb demonstrated in all 5 cell lines an ubiquitous 
expression of non-phosphorylated CXCR4 throughout the 
cell, with distinct immunofluorescent foci at the plasma 
membrane, within the cytoplasm and particularly around 
or within the nuclear compartment, as showed by the co-
localization with the DAPI labeling (Figure 4). Although 
diffusely positive within the cell nuclei, CXCR4 was 
absent in nucleoli (Figure 5C).
To explore possible interconnections between the 
subcellular localization of non-phosphorylated, thus 
functionally bioavailable CXCR4 and the occurrence of 
EMT in NET cell lines, both confocal microscopy and 
western blot analysis after biochemical fractionation of 
nuclear and extra-nuclear components were also used. In 
CXCL12- or TGF-β1-treated NET cells with CXCR4high/
CXCL12low phenotype, we noted a striking increase of 
the CXCR4-related FITC fluorescence in cell nuclei 
(Figure 5C–5D). This finding was further confirmed 
by computational analysis of the nuclear density of 
CXCR4 using the NIS software. In fact, as depicted in 
Figure 5E, the mean number of pixels emitted by the 
FITC fluorochrome in the nuclear area were significantly 
increased in BON1 (p < 0.0001), CM (p = 0.0004) and 
QGP1 cells (p = 0.006) by stimulation with either CXCL12 
or TGF-β1, while remained unchanged in H727 and CNDT 
2.5 cell lines. These data suggest that an apparent nuclear 
translocation of ligand-actionable CXCR4 occurs in NET 
cells exposed to EMT-inducing stimuli as provided by 
CXCL12 or TGF-β1.
To further verify our data, western blot experiments 
were completed after biochemical fractionation of NET 
cell lines in nuclear and non-nuclear aliquots. As shown in 
Figure 6A, the monomeric isoform of non-phosphorylated 
CXCR4 (45 kDa) was dually expressed in both nuclear 
and non-nuclear fractions in all cell lines. In H727 
and CNDT 2.5 cells, no effect was detected following 
CXCL12 treatment in terms of CXCR4 expression 
(Figure 6B). On the other hand, CXCL12 induced a 
significant overexpression of the nuclear fraction of 
non-phosphorylated CXCR4 in BON1 and CM cells 
(p = 0.01 and p = 0.04, respectively). In QGP1 cell lines 
the upregulation of nuclear CXCR4 approached statistical 
significance (p = 0.08). Of interest, in BON1 cells, the 
majority of unbound CXCR4 was compartmentalized 
within the nuclei both at baseline and after CXCL12 
treatment. The purity of the subcellular aliquots extracted 
from each cell line was confirmed by detection of lamin 
A/C and GAPDH in the nuclear and extra-nuclear 
fractions, thus excluding that the presence of CXCR4 in 
the nuclei was due to non-nuclear contamination. There 
was an excellent degree of correlation between the levels 
of nuclear CXCR4/Lamin A by western blot, and the 
intensity of nuclear fluorescence emitted by CXCR4, as 
assessed by computational analysis of confocal microscopy 
images (r = 0.87; p = 0.03).
CXCR4 silencing disables EMT occurrence in 
NET cell lines 
To verify the functional relevance of CXCR4 in 
supporting EMT in CXCR4high/CXCL12low NET cell 
lines, CXCR4 loss-of-function studies were carried out. 
Receptor knockdown by siRNA treatment was confirmed 
by qualitative PCR, RT-PCR, and confocal microscopy. 
Figure 7A–7C and Supplementary Figure 4A show 
that both mRNA and protein levels of CXCR4 were 
dramatically reduced in siRNA-treated NET cells, but 
not in mock- or scramble-treated cells. Remarkably, very 
weak-to-no membrane and nuclear immunolabeling was 
detectable in CXCR4-silenced cells, thus confirming the 
specificity of the UMB-2 mAb.
Changes in intrinsic and CXCL12-enhanced bone 
tropism of NET cell lines were evaluated before and after 
siRNA transfection, as summarized in Figure 7E. CXCR4 
knockdown significantly reduced the migration towards 
the bone in BON1 and QGP1 cells. Moreover, after 
CXCR4 silencing, CXCL12 was unable to upregulate the 
in vitro bone tropism of both BON1, CM and QGP1 cells. 
Similarly, the invasive potential of CXCR4high/CXCL12low 
NET cell lines was not altered by CXCL12 following anti-
CXCR4 siRNA transfection (Supplementary Figure 4B), 
thus suggesting that the previously documented pro-
migratory and pro-invasive effects of this cytokine were 
specifically mediated by CXCR4 itself.
To further confirm the role of CXCR4 as critical 
regulator of EMT in NET cell lines, we assessed the EMT-
related transcriptional profile of CXCR4-silenced cells 
after 2 hr-CXCL12 stimulation. As expected, in CXCR4-
silenced cells CXCL12 was unable to induce substantial 
modifications in the expression of EMT-related genes 
(CDH1, CDH2, EPCAM, CXCR4, TGF-β1, SNAIL, CTGF, 
IL11, PTHrP, RANK, MMP9 and MMP13), as proven by 
mRNA levels that were, indeed, comparable with those 
of untreated, mock- and scramble-treated NET cells (data 
not shown). Consistently with these observations, we also 
found that silencing of CXCR4 inhibited the acquisition 
of a mesenchymal phenotype in response to CXCL12. 
In fact, no changes in the shape of siRNA-transfected 
BON1, CM, and QGP1 cells were observed following 
the stimulation with the chemokine as compared with 
untreated control cells. Representative experiments with 
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Figure 4: CXCL12 induces modifications in NET cell morphology. Changes in NET cell morphology upon CXCL12 or TGF-β1 
stimulation were assessed by confocal microscopy. At baseline, both BON1 (A) and H727 cells (D) showed a round or irregularly polygonal 
shape. After either CXCL12 (B) or TGF-β1 treatment (C), BON1 cells as CXCR4high/CXCL12low cells, acquired a mesenchymal shape. 
By contrast, the morphology of H727 cells, representative of CXCR4low/CXCL12high cell lines, remained unchanged after either CXCL12 
(E) or TGF-β1 (F). In QGP1 cells (H), CXCL12 induced the formation of pseudopodia (white arrows), which were not present in control 
preparations (G). A 3D reconstruction of QGP1 cells demonstrates the subcellular localization of non-phosphorylated CXCR4 (FITC, 
green) in both the cytomembranous and nuclear compartments (I). Nuclei are stained in blue (DAPI), whereas cytoskeletal F-actin is 
stained in red (phalloidin). Following CXCL12 or TGF-β1 treatment, there was a significant increase of the spindle index in BON1, CM 
and QGP1 cells (J). Mean, 95% confidence interval and outliers are depicted by box and whisker plots.
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Figure 5: Activation of EMT is associated with CXCR4 nuclear accumulation. The nuclear localization of CXCR4 in NET 
cell lines was revealed by ICC, as represented here in CM cells. Both a polyclonal (A) or monoclonal (B) Abs were used, resulting in minor 
staining differences. The nuclear accumulation of non-phosphorylated CXCR4 molecules (white arrows) was also detected by confocal 
microscopy (C). CXCL12 treatment (similarly to TGF-β1 treatment, not shown) led to a significant increase of the CXCR4-related FITC 
nuclear intensity (D). These data were confirmed by computational analysis of the CXCR4 nuclear density. As represented by box and 
whisker plots, the mean number of FITC pixels emitted within the nuclear area significantly increased following incubation with CXCL12 
in CXCR4high/CXCL12low NET cell lines (BON1, CM, QGP1).
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Figure 6: Nuclear accumulation of CXCR4 following its agonist stimulation is predominant in CXCR4high/CXCL12low 
NET cell lines. After biochemical fractionation, nuclear and non-nuclear aliquots of NET cells were probed with the anti-CXCR4 mAb 
UMB-2, which recognizes the receptor only when inactive and non-phosphorylated. Western blot showed a significant upregulation of the 
nuclear expression of the actionable fraction of CXCR4 following CXCL12 incubation in both BON1 and CM cell lines. In QGP1 cells, 
the upregulation of nuclear CXCR4 approached statistical significance (p = 0.08).  No substantial modifications were seen in CXCR4low/
CXCL12high NET cell lines treated with CXCL12. Interestingly, the non-nuclear expression of non-phosphorylated CXCR4 was not 
significantly influenced by CXCL12 in all cell lines. Lamin A/C and GAPDH were internal controls in both nuclear and non-nuclear 
preparations, respectively.
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BON1 cells are shown in Figure 7C–7D. Analysis of the 
spindle index showed no difference between control cells 
and CXCL12-treated NET cells after CXCR4 deprivation 
(Supplementary Figure 5). 
Taken together, these findings provide a definite 
evidence that the EMT-promoting signals conveyed by 
CXCL12 are critically sensed by CXCR4 which regulates 
transcriptional, conformational and functional modifications 
that promote the osteotropism in NET cell lines.
DISCUSSION
This study defines the role of the CXCL12/
CXCR4 axis in the biology of bone-colonizing NETs, at 
least in vitro. It demonstrates that the EMT-promoting 
signals conveyed by CXCL12 to NET cells are critically 
sensed by surface CXCR4 leading to transcriptional, 
structural and functional modifications that culminate in 
enhanced tumor osteotropism. Moreover, it shows that the 
bioavailable fraction of CXCR4 accumulates within the 
nuclei of EMT-undergoing NET cells, thus suggesting that 
unique functions of the receptor may segregate according 
to its subcellular distribution.
NETs are curable only when localized, but up to 
95% of patients are diagnosed at stage IV [17]. In most 
recent phase III trials of advanced NETs, the skeleton is 
a frequent site of metastases [18, 19], and the association 
between NET bone colonization and poor patient outcome 
is consistently reported by retrospective studies [4, 5]. 
Based on these premises, osteotropic NETs can be seen as 
aggressive subtypes of these tumors and the identification 
of their molecular hallmarks may be helpful in the 
prevention and development of new therapies.
In the present study, we investigated the CXCL12/
CXCR4 axis in multiple cell lines representative of 
pancreatic, ileal and bronchial NETs. We found that 
the pancreatic BON1, CM and QGP1 NET cell lines 
expressed membrane CXCR4 at high density, but only in 
Figure 7: Silencing of CXCR4 reverts the EMT-like changes induced by CXCL12 in NET cells. The transfection efficiency 
of the anti-CXCR4 siRNA was evaluated by qualitative PCR (A), RT-PCR (B) and confocal microscopy (C). Overall, siRNA treatment 
induced a reduction of CXCR4 mRNA up to 70% in BON1 cells, as compared with original control values. A similar decrease was observed 
in terms of protein expression in the same cell line. (D) After incubation with CXCL12, siRNA-treated BON1 cells maintained a polygonal 
shape. (E) Silencing of CXCR4 reduced the migratory potential of CXCR4high/CXCL12low NET cells, even following CXCL12 treatment.
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a relatively small percentage of cells, namely up to 27%. 
In spite of an overlapping percentage of positivity, other 
NET cells as H727 and CNDT 2.5, displayed a three-fold 
lower density of CXCR4. However, an inverse correlation 
between CXCR4 expression and CXCL12 secretion was 
also observed in our work, that dichotomically categorized 
BON1, CM and QGP1 as CXCR4high/CXCL12low NET cell 
lines and H727 and CNDT 2.5 as CXCR4low/CXCL12high 
cells. In this context, an autocrine regulatory loop between 
CXCL12 and CXCR4 can be hypothesized also for NETs, 
since evidence in other cancers suggests that persistent 
ligand stimulation causes CXCR4 degradation, as well 
as epigenetic regulation of the entire molecular synapse 
[7, 20, 21].The putative association between CXCR4 
overexpression, EMT activation and increased risk of 
NET bone metastases [3] led us to hypothesize a selection 
process whereby the activation of the CXCL12/CXCR4 
axis skews NET cells toward a preponderance of EMT-
upregulated clones. To test this hypothesis, we first ruled 
out the proliferation effects of CXCL12 on NET cell lines, 
since an accelerated proliferation could justify per se a 
more aggressive tumor behavior, thus promoting higher 
rates of skeleton colonization. In our hands, CXCL12 was 
inert on NET cell proliferation, in line with work from 
others [9].
According to the “metastasis seed pre-selection” 
hypothesis [22], the tumor spread to distant organs is 
related to peculiar gene signatures of the primary tumors. 
Therefore, we investigated the effects of CXCL12 on 
the in vitro osteotropism of NET cells, and correlated 
the migratory changes with transcriptional modifications 
induced by agonist stimulation of CXCR4. Notably, 
only CXCR4high/CXCL12low pNET cell lines BON1 and 
QGP1 displayed intrinsic migratory and invasive potential 
towards the bone, in line with the increased osteotropism 
observed in patients with pNETs. Indeed, significantly 
higher odds of bone colonization have been recently shown 
for pNETs as compared with all other NET primaries 
[23]. In CXCR4low/CXCL12high NET cell lines, autocrine 
stimulation by CXCL12 probably inhibited  cell homing 
to the bone as result of an inadequate gradient effect. 
These findings appear in line with other studies correlating 
the CXCR4 upregulation/CXCL12 downregulation in 
tumor cells with their enhanced spreading to CXCL12-
overexpressing sites [13, 24]. Intriguingly, when evaluated 
in their baseline transcriptional profile, CXCR4high/
CXCL12low NET cell lines show the signature of partial 
EMT [6], namely low levels of both CDH1 and EpCAM 
expression. In this context, the association between 
functional and transcriptional features of BON1 cells was 
paradigmatic. In fact, while being the only cell line with 
both migratory and invasive intrinsic potential, BON1 
showed a profile characterized by high CXCR4 and CTGF 
transcription in the presence of downregulated TGF-β1. 
This specific EMT signature was described in our previous 
work as predictive of NET bone colonization [3].
Agonist stimulation of CXCR4 significantly 
increased the migratory/invasive capabilities of 
CXCR4high/CXCL12low NET cell lines, whereas no effect 
was detected on CXCR4low/CXCL12high NET cells. This 
finding depicts several aspects of the CXCL12/CXCR4 
biology in these tumors. First, CXCL12 is not only 
involved in migration of NET cells, but is also able to 
enhance their sensitivity to the complex cytokine milieu 
of the bone marrow. Second, transient administration of 
exogenous CXCL12 or chronic production of endogenous 
CXCL12 may apparently have opposite effects on NET 
cell migration and invasiveness. This effect has been 
already reported in colorectal cancer [25].
Changes of the in vitro osteotropism of NET cell 
lines following CXCL12 incubation were paralleled 
by concomitant modifications in the EMT-related 
transcriptional profile. Indeed, while being inactive in 
CXCR4low/CXCL12high NET cell lines, CXCR4 agonist 
stimulation caused an EMT-like transcriptional shift in the 
CXCR4high/CXCL12low counterpart. This was particularly 
evident in CM and QGP1 cells, in which CXCL12 
promoted a complete cadherin switch along with SNAIL, 
CXCR4 and IL-11 overexpression. In the BON1 cell line, 
bearing remarkable signs of partial EMT at baseline, the 
CXCL12-induced transcriptional modifications were less 
evident, although present and still able to increase the 
cellular invasiveness.
To further support our hypothesis that CXCL12 
elicits EMT in specific subsets of NET cells, we compared 
the transcriptional changes induced by CXCL12 or TGF-β1 
in cell lines. TGF-β1 can act as either promoter, via EMT 
activation, or suppressor of tumor progression, depending 
on the degree of tumor malignancy [26]. In this context [3], 
we have reported its protective role in low-to-intermediate 
grade carcinoids, but the higher malignancy of NET cell 
lines is well documented [27, 28]. Therefore, here we used 
TGF-β1 as positive regulator of EMT and observed that 
this cytokine induced the transcriptional signature of EMT 
in all NET cell lines, with modifications similar to those 
caused by CXCL12 in CXCR4high/CXCL12low NET cells.
When evaluated in their morphology upon 
stimulation with CXCL12 or TGF-β1, NET cells underwent 
similar changes. Both cytokines, indeed, prompted 
CXCR4high/CXCL12low NET cells to acquire a mesenchymal 
shape including the presence of pseudopodia, whereas no 
significant changes were revealed in H727 and CNDT 2.5 
cells. Why CXCR4low/CXCL12high NET cells treated with 
TGF-β1 remained morphologically unchanged during EMT 
activation is unclear. However, subliminal stimulation of 
the EMT-activating machinery or lack of other convergent 
stimuli for the full EMT activation can be hypothesized.
To ascertain that the EMT-promoting signals 
conveyed by CXCL12 were specifically sensed by CXCR4 
in NET cell lines, we carried out loss-of-function studies 
via siRNA silencing. Knockdown of CXCR4 was able to 
revert the CXCL12-induced EMT phenotype in CXCR4high/
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CXCL12low NET cell lines. In particular, both transcriptional, 
conformational and pro-migratory effects of CXCL12 
were silenced in cells lacking the expression of CXCR4, 
thus supporting its crucial role in mediating the effects of 
CXCL12. Although CXCR4 is a membrane receptor, its 
intracellular segregation following CXCL12 stimulation 
has been widely reported and associated with high tumor 
malignancy [7, 29–32]. We have previously documented 
a positive nuclear staining in primary NETs by IHC 
using a polyclonal anti-CXCR4 Ab [3], whereas a purely 
membranous expression of the receptor was described by 
Kaemmerer et al. in both lung and gastroenteropancreatic 
NETs employing the anti-CXCR4 mAb UMB-2 [10, 11]. 
Here, we investigated the subcellular expression of CXCR4 
in NET cell lines by using both Abs Although in the presence 
of a more defined cytomembranous staining with UMB-2, 
both Abs definitely showed nuclear immunoreactivity 
for CXCR4. Both the relatively low concentration of the 
mAb used (1:200, as compared with 1:100 in [30]) and 
the absence of immunoreactivity in CXCR4-silenced cells 
supported the specificity of our findings.
Ligand stimulation of CXCR4 induces 
phosphorylation of several serine residues in the C-terminal 
domain of the receptor, thus leading to stabilization of the 
interaction with β-arrestin and receptor internalization 
[21, 33, 34]. Evidence demonstrates that the UMB-2 
mAb is phosphosensitive, and binds CXCR4 only when 
the C-terminal epitope is non-phosphorylated and the 
receptor consequently inactive [33]. Here, we observed 
accumulation of the non-phosphorylated fraction of CXCR4 
in the nuclei of CXCR4high/CXCL12low NET cell lines 
following incubation with CXCL12 or TGF-β1. Although 
the origin and functional relevance of nuclear CXCR4, 
as well as the mechanisms enrolled in its translocation 
are undefined, the direct involvement of functionally 
bioavailable CXCR4 in the transcriptional activation of 
EMT cannot be excluded. Future research is thus needed 
to characterize the nuclear activity of CXCR4 as part of the 
transcriptional machinery driving the EMT process, and/or 
as modulator of the secondary G-protein coupled receptor 
(GPCR) signals that regulate the EMT at the nuclear level. 
Interaction between the nuclear pool of both CXCR4 and 
protein G
αi
 has been already documented in prostate cancer 
[35], and supports the hypothesis that CXCR4 may regulate 
the signaling from inside the nucleus.
All the investigations described in the present work 
have been carried out using immortalized cell lines. Since 
the genomic and biologic resemblance of NET cell lines 
and their primary tumor counterparts has been repeatedly 
questioned [27, 36–38], extrapolation of our findings to 
the clinical scenario should be performed very carefully. 
In this context, as skepticism has been raised particularly 
regarding the authenticity of the neuroendocrine 
background of CNDT 2.5 cells [39], findings related to 
this cell line, representative of midgut carcinoids or of 
non-NET tumors expressing CXCR4 at low levels, should 
be interpreted with particular caution.
Although bearing the limitations of an in vitro only 
study, this work shed lights on several mechanisms by 
which NET cells colonize the skeleton, and paves the way 
to new therapies for these tumors. Since CXCR4 agonism 
seems to act as a robust promoter of EMT in NETs, 
CXCR4 antagonism may be of therapeutic interest. Prior 
work has demonstrated that direct blockade of CXCR4 
by AMD3100 exerts antiproliferative effects in NETs 
[9], but its anti-metastatic properties via EMT-inhibition 
have never been explored. In multiple myeloma, the anti-
CXCR4 mAb ulocuplumab was recently shown to inhibit 
the malignant plasma cell dissemination by suppressing 
the EMT-like phenotype [40], and similar effects cannot be 
excluded in NETs. Given that the subcellular distribution 
of CXCR4 may influence its function, and that nuclear 
translocation of its bioavailable fraction is consistently 
noted in NET cells undergone EMT, nuclear import 
machinery modulators should be tested in their anti-EMT 
or anti-osteotropic properties in these malignancies.
MATERIALS AND METHODS
Cell lines, patient tissue and cytokines 
The lung carcinoid H727 cell line was purchased 
from the American Type Cell Collection (ATCC, Milan, 
Italy) and was verified at our institution as recommended 
(ATCC Technical Bulletin no. 8; Manassas, ATCC; 2008). 
BON1, CM and QGP1 pancreatic NET cell lines were 
kindly provided by Dr. M. Donadelli (University of Verona, 
Italy), while midgut carcinoid CNDT 2.5 cells were a gift 
from Dr. L.E. Lee (M.D. Anderson Cancer Center, Houston, 
TX, USA). BON1 and CNDT 2.5 cells were cultured in 
DMEM F12 (Gibco, Life Technologies, Turin, Italy) 
complete medium. For CNDT 2.5 cells, sodium pyruvate, 
MEM vitamin solution and MEM nonessential amino acids 
(Gibco) were added, as previously described [41]. QGP1, 
CM and H727 cell lines were grown in 10% FCS RPMI 
1640 and maintained at 37°C in a 5% CO2-incubator.
Healthy bone fragments of 3–5 mm3 including 
equivalent amounts of cortical/spongy bone were obtained 
from de-identified patients undergoing post-traumatic 
orthopedic surgery, according to a protocol approved by 
the Ethical Committee of the University of Bari. CXCL12 
(R&D Systems, Minneapolis, MN, USA) was diluted in 
PBS, whereas TGF-β1 (PeproTech, Rocky Hill, NJ, USA) 
was suspended in 10 mM citric acid at pH 3.
Assessment of CXCR4 expression and CXCL12 
secretion 
Flow cytometry investigated the expression of 
membrane CXCR4 in NET cell lines. After 2 hr of 
incubation with or without CXCL12 at 100 ng/ml, 1 × 105 
cells at ~70% confluency were mechanically detached 
and incubated at room temperature for 20 minutes in 
dark with 5 μl/100 μl of the APC-conjugated anti-human 
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CXCR4 mAb (Affymetrix, Santa Clara, CA, USA). Human 
lymphocytes from healthy donors served as positive control 
cells, while APC-conjugated mouse IgG2a (Beckman 
Coulter, Brea, CA, USA) were used for isotypic controls. 
After repeated PBS washing, the cells were analyzed by 
FACScanto (Becton-Dickinson, Mountain View, CA, 
USA) for both percentage of positive cells and MFI. MFI 
ratios were calculated by dividing the MFI for CXCR4 by 
the mean fluorescence of the respective nonspecific isotype 
control, as reported elsewhere [42]. Secretion of CXCL12 
by NET cell lines was measured by ELISA (Abcam, 
Cambridge, MA, USA), as described [43].
Proliferation assays 
To test the effects of CXCL12 on NET cell 
proliferation, the 3-(4,5-dimethylthiazol-2yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS) assay (Promega, Madison, WI, USA) was carried 
out [44]. Briefly, cells were incubated with CXCL12 at 
25, 50, 100 ng/ml and analyzed after 24, 48 and 72 hr. 
The proliferation was then estimated with respect to the 
absorbance of untreated controls in biological triplicates.
Migration and invasion assays 
To assess the in vitro osteotropism of NET cell lines, 
we used 24-well plates including BD FalconTM cell culture 
8 μm inserts, and BD BioCoatTM MatrigelTM invasion 
chambers (Becton Dickinson Bioscience, Bedford, MA, 
USA) for migration and invasion assays, respectively. 
Briefly, after overnight serum starvation, cells (104/well) 
were seeded onto the upper chamber of the inserts, while 
1% FCS RPMI 1640 was added to the lower chamber in 
the presence or absence of bone fragments. After 24h of 
incubation, cells on the upper surface of the membrane 
were removed with a cotton swab, while cells adhering to 
the underside of the insert were fixed with formaldehyde, 
then stained with 4′,6-diamidino-2-phenylindole 
dihydrochloride (DAPI; Sigma Aldrich), and finally 
counted in ten random fields at 40x magnification under 
a UV microscope (Leica DMRE, Heidelberg, Germany). 
NET cells pretreated with CXCL12 at 100 ng/ml for 2 hr 
were similarly tested in their migratory and invasive 
potential. Each experiment was performed in triplicate.
EMT-related transcriptional profile 
Real time (RT)-PCR was used to determine the 
expression levels of the EMT markers CDH1 (coding for 
E-Cadherin), CDH2 (coding for N-Cadherin), EPCAM, 
CXCR4, TGF-β1, SNAIL, CTGF, IL11, PTHrP, RANK, 
MMP9 and MMP13 in NET cell lines. mRNA levels were 
compared after logarithmic transformation of the raw CT 
data (2–∆Ct) [45]. Gene transcription was then assessed 
after 2 or 24 hr treatment with CXCL12 at 100 ng/ml 
or TGF-β1 at 50 ng/ml as positive control for EMT 
[6, 14, 15], and compared with expression levels in 
relative untreated preparations using the 2-∆∆Ct method [45]. 
Specific primers used for mRNA amplification are listed in 
SupplementaryTable 1. β-actin was used as housekeeping 
gene.
Cell morphology and CXCR4 subcellular 
localization 
After relative incubations, NET cells were fixed in 
paraformaldehyde, permeabilized by 0.1% Triton X-100 
(Sigma Aldrich) and incubated overnight at 4°C with 
a rabbit anti-CXCR4 mAb (UMB2 clone, ab124824, 
Abcam) at 1:200 dilution. Cells were then incubated 
at room temperature with a secondary goat anti-rabbit 
FITC-conjugated Ab, while TRITC-conjugated Phalloidin 
(P1951, Sigma Aldrich) and DAPI were used to visualize 
the cytoplasmic and nuclear compartments, respectively. 
Samples were analyzed under a confocal laser scanning 
microscope (C2plus, Nikon Instr., Lewisville, TX, USA), 
and imaged in sequential scan mode. A dedicated software 
(NIS element software, Nikon Instr) was used for pixel count 
and analysis of nuclear-FITC intensity. As a measure of 
mesenchymal phenotype, the spindle index was calculated 
as ratio of maximum length to maximum width of at least 
100 cells from 10 random fields observed at 40X [16].
CXCR4 was also investigated by 
immunocytochemistry (ICC) using either a rabbit 
polyclonal (ab2074, Abcam) or monoclonal Ab (UMB2 
clone, Abcam). Briefly, NET cells were fixed in 
paraformaldehyde (Sigma Aldrich) and then incubated 
overnight at 4°C with the primary polyclonal (dilution: 
1:100) or monoclonal (dilution: 1:200) anti-CXCR4 Ab, 
using human lymphocytes as positive controls. After 
treatment with a biotinylated anti-rabbit secondary Ab 
(Vector Laboratories, Burlingame, CA, USA), CXCR4 
expression was revealed by the diaminobenzidine reaction 
and the slides were inspected under a light microscope. 
Immunoreactivity was scored as described [3].
Western blot
Nuclear and cytoplasmic NET cell fractions were 
prepared by NE-PER extraction kit (Life Technologies) 
and 10 μg of cytoplasmic- or nuclear-purified protein 
lysates from both treated and untreated cells were 
investigated by Western blot with the rabbit anti-CXCR4 
mAb UMB-2 (Abcam) at 1:1000 dilution. Lamin A/C and 
GAPDH detection was used as intra-assay control for both 
purity and loading of nuclear and non-nuclear fraction 
lysates, respectively. The density of CXCR4 bands was 
calculated by ImageQuantTL (GE Healthcare, Little 
Chalfont, UK) with respect to Lamin A/C or GAPDH in 
three different experiments whose values were expressed 
as mean ± SD.
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CXCR4 loss-of-function studies
To assess its role in EMT, CXCR4 was silenced in 
BON1, CM and QGP1 cells by using small interfering RNA 
(siRNA). Scramble probes (Ambion, Life Technologies, 
Carlsbad, CA, USA) were used as control. Two sense 
(GGCAGUCCAUGUCAUCUACtt; GGAAGCUGU 
UGGCUGAAAAtt) and two antisense oligonucleotides 
(GUAGAUGACAUGGACUGCCtt; UUUUCAGCCAA 
CAGCUUCCtt; Ambion) were combined for the 
silencing procedure [46]. Briefly, cells were seeded at 
500,000/well and then transfected 4 hrs later by adding 
3 µl/well of Lipofectamine 3000 Reagent (Invitrogen, 
Carlsbad, CA, USA) and siRNAs at a final concentration 
of 60 nmol/L. CXCR4-silenced cells were thus evaluated 
in their migratory and invasive capabilities, EMT-related 
transcriptional profile, and cell morphology.
Statistical analysis
Data were analyzed using Student’s t-test or one-
way ANOVA with Bonferroni post-test, as appropriate. 
The Spearman test was used for correlation analysis. All 
tests were two-sided, and a p-value <0.05 was considered 
statistically significant. Statistical analysis was performed 
using GraphPad Prism 5 software (GraphPad Software, La 
Jolla, CA, USA).
ACKNOWLEDGMENTS
Authors thank Morena D’Avenia, Ilaria Maggio and 
Sebastiano Acquaviva for technical assistance.
CONFLICTS OF INTEREST
The Authors declare no affiliation with industries or 
organizations with a financial interest, direct or indirect, that 
may affect the conduct or reporting of the work submitted.
GRANT SUPPORT
This work was supported by a grant from the Italian 
Association for Cancer Research (AIRC, IG17536), 
Umberto Veronesi Foundation (Post-Doctoral Fellowship, 
2016) and Apulia Region (Oncogenomic Project, 2015).
REFERENCES
1. Cives M, Strosberg J. An update on gastroenteropancreatic 
neuroendocrine tumors. Oncology (Williston Park). 2014; 
28:749–756.
2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, 
Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. 
One hundred years after "carcinoid": epidemiology of and 
prognostic factors for neuroendocrine tumors in 35,825 cases 
in the United States. J Clin Oncol. 2008; 26:3063–3072.
 3. Cives M, Rizzo F, Simone V, Bisceglia F, Stucci S, 
Seeber A, Spizzo G, Montrone T, Resta L, Silvestris F. 
Reviewing the Osteotropism in Neuroendocrine Tumors: 
The Role of Epithelial-Mesenchymal Transition. 
Neuroendocrinology. 2015; 103:321–334.
 4. Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, 
Ramirez MT, Bobiak S, Nakakura EK, Venook AP, 
Shah MH, Bergsland EK. Bone metastases and skeletal-
related events from neuroendocrine tumors. Endocr 
Connect. 2014; 4:9–17.
 5. Kavecansky J, Wei L, Caronia L, Ramirez MT, 
Bloomston M, Shah MH. Bone Metastases in Well-
toModerately Differentiated Neuroendocrine Tumors: A 
Single Institutional Review From the Ohio State University 
Medical Center. Pancreas. 2015; 44:198–203.
 6. Ye X, Weinberg RA. Epithelial-Mesenchymal Plasticity: A 
central regulator of cancer progression. Trends Cell Biol. 
2015; 25:675–686.
 7. Guo F, Wang Y, Liu J, Mok SC, Xue F, Zhang W. CXCL12/
CXCR4: a symbiotic bridge linking cancer cells and their 
stromal neighbors in oncogenic communication networks. 
Oncogene. 2016; 35:816–826.
 8. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, 
McClanahan T, Murphy E, Yuan W, Wagner SN, 
Barrera JL, Mohar A, Verástegui E, et al. Involvement of 
chemokine receptors in breast cancer metastasis. Nature. 
2001; 410:50–56.
 9. Circelli L, Sciammarella C, Guadagno E, Tafuto S, del 
Basso de Caro M, Botti G, Pezzullo L, Aria M, Ramundo V, 
Tatangelo F, Losito NS, Ieranò C, D'Alterio C, et al. 
CXCR4/CXCL12/CXCR7 axis is functional in 
neuroendocrine tumors and signals on mTOR. Oncotarget. 
2016; 7:18865–75.
10. Kaemmerer D, Reimann C, Specht E, Wirtz RM, Sayeg M, 
Baum RP, Schulz S, Lupp A. Differential expression and 
prognostic value of the chemokine receptor CXCR4 in 
bronchopulmonary neuroendocrine neoplasms. Oncotarget. 
2015; 6:3346–3358.
11. Kaemmerer D, Träger T, Hoffmeister M, Sipos B, 
Hommann M, Sänger J, Schulz S, Lupp A. Inverse 
expression of somatostatin and CXCR4 chemokine receptors 
in gastroenteropancreatic neuroendocrine neoplasms of 
different malignancy. Oncotarget. 2015; 6:27566–27579.
12. Deschamps L, Bacha D, Rebours V, Mebarki M, Bretagnol F, 
Panis Y, Bedossa P, Ruszniewski P, Couvelard A. The 
expression of the hypoxia markers CA9 and CXCR4 is 
correlated with survival in patients with neuroendocrine 
tumours of the ileum. Neuroendocrinology. 2012; 95:214–222.
13. Arvidsson Y, Bergström A, Arvidsson L, Kristiansson E, 
Ahlman H, Nilsson O. Hypoxia stimulates CXCR4 
signalling in ileal carcinoids. Endocr Relat Cancer. 2010; 
17:303–316.
14. Lamouille S, Xu J, Derynck R. Molecular mechanisms of 
epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 
2014; 15:178–96.
Oncotarget15www.impactjournals.com/oncotarget
15. Katsuno Y, Lamouille S, Derynck R. TGF-β signaling and 
epithelial-mesenchymal transition in cancer progression. 
Curr Opin Oncol. 2013; 25:76–84.
16. Koo V, El Mekabaty A, Hamilton P, Maxwell P, Sharaf O, 
Diamond J, Watson J, Williamson K. Novel in vitroassays 
for the characterization of EMT in tumourigenesis. Cell 
Oncol. 2010; 3267–76.
17. Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, 
Salem R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain V, 
Davidson B, Siegler M, Caplin M et al. Recommendations 
for management of patients with neuroendocrine liver 
metastases. Lancet Oncol. 2014; 15:e8–21.
18. Strosberg JR, Wolin EM, Chasen B, Kulke MH, 
Bushnell DL, Caplin ME, Baum RP, Kunz PL, Hobday TJ, 
Hendifar AE, Oberg KE, Lopera Sierra M, Kwekkeboom DJ, 
et al. NETTER-1 phase III: Progression-free survival, 
radiographic response, and preliminary overall survival 
results in patients with midgut neuroendocrine tumors 
treated with 177-Lu-Dotatate. J Clin Oncol. 2016; 
34:abstract 194.
19. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, 
Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, 
Rouyrre N, Sachs C, et al. RAD001 in Advanced 
Neuroendocrine Tumours, Fourth Trial (RADIANT-4) 
Study Group. Everolimus for the treatment of advanced, 
non-functional neuroendocrine tumours of the lung 
or gastrointestinal tract (RADIANT-4): a randomised, 
placebocontrolled, phase 3 study. Lancet. 2016; 387:968–77.
20. Hoffmann F, Müller W, Schütz D, Penfold ME, Wong YH, 
Schulz S, Stumm R. Rapid uptake and degradation of 
CXCL12 depend on CXCR7 carboxylterminal serine/
threonine residues. J Biol Chem 2012; 287:28362–77.
21. Marchese A, Benovic JL. Agonist-promoted ubiquitination 
of the G protein-coupled receptor CXCR4 mediates 
lysosomal sorting. J Biol Chem 2001; 276:45509–12.
22. Zhang XH, Jin X, Malladi S, Zou Y, Wen YH, Brogi E, 
Smid M, Foekens JA, Massagué J. Selection of bone 
metastasis seeds by mesenchymal signals in the primary 
tumor stroma. Cell. 2013; 154:1060–73.
23. Riihimäki M, Hemminki A, Sundquist K, Sundquist J, 
Hemminki K. The epidemiology of metastases in 
neuroendocrine tumors. Int J Cancer 2016; 139:2679–2686.
24. Zhou W, Jiang Z, Liu N, Xu F, Wen P, Liu Y, Zhong W, 
Song X, Chang X, Zhang X, Wei G, Yu J. Down-
regulation of CXCL12 mRNA expression by promoter 
hypermethylation and its association with metastatic 
progression in human breast carcinomas. J Cancer Res Clin 
Oncol. 2009; 135:91–102.
25. Drury LJ, Wendt MK, Dwinell MB. CXCL12 chemokine 
expression and secretion regulates colorectal carcinoma cell 
anoikis through Bim-mediated intrinsic apoptosis. PLoS 
One. 2010; 5:e12895.
26. Massagué J, Blain SW, Lo RS. TGFbeta signaling in 
growth control, cancer, and heritable disorders. Cell. 2000; 
103:295–309.
27. Grozinsky-Glasberg S, Shimon I, Rubinfeld H. The 
role of cell lines in the study of neuroendocrine tumors. 
Neuroendocrinology. 2012; 96:173–87.
28. Fraedrich K, Schrader J, Ittrich H, Keller G, Gontarewicz A, 
Matzat V, Kromminga A, Pace A, Moll J, Bläker M, 
Lohse AW, Hörsch D, Brümmendorf TH, et al. Targeting 
aurora kinases with danusertib (PHA-739358) inhibits 
growth of liver metastases from gastroenteropancreatic 
neuroendocrine tumors in an orthotopic xenograft model. 
Clin Cancer Res. 2012; 18:4621–32.
29. Pelekanos RA, Ting MJ, Sardesai VS, Ryan JM, Lim YC, 
Chan JK, Fisk NM. Intracellular traffiking and endocytosis 
of CXCR4 in fetal mesenchymal stem/stromal cells. BMC 
Cell Biol. 2014; 15:15.
30. Fischer T, Nagel F, Jacobs S, Stumm R, Schulz S. 
Reassessment of CXCR4 chemokine receptor expression in 
human normal and neoplastic tissues using the novel rabbit 
monoclonal antibody UMB-2. Plos One 2008; 3:e4069.
31. Yoshitake N, Fukui H, Yamagishi H, Sekikawa A, Fujii S, 
Tomita S, Ichikawa K, Imura J, Hiraishi H, Fujimori T. 
Expression of SDF-1 alpha and nuclear CXCR4 predicts 
lymph node metastasis in colorectal cancer. Br J Cancer 
2008; 98:1682–9.
32. Speetjens FM, Liefers GJ, Korbee CJ, Mesker WE, 
van de Velde CJ, van Vlierberghe RL, Morreau H, 
Tollenaar RA, Kuppen PJ. Nuclear localization of CXCR4 
determines prognosis for colorectal cancer patients. Cancer 
Microenviron 2009; 2:1–7.
33. Mueller W, Schütz D, Nagel F, Schulz S, Stumm R. 
Hierarchical organization of multi-site phosphorylation at 
the CXCR4 C terminus. PLoS One 2013; 8:e64975.
34. Busillo JM, Armando S, Sengupta R, Meucci O, Bouvier M, 
Benovic JL. Site-specific phosphorylation of CXCR4 is 
dynamically regulated by multiple kinases and results in 
differential modulation of CXCR4 signaling. J Biol Chem. 
2010; 285:7805–17.
35. Don-Salu-Hewage AS, Chan SY, McAndrews KM, 
Chetram MA, Dawson MR, Bethea DA, Hinton CV. 
Cysteine (C)-x-C receptor 4 undergoes transportin 
1-dependent nuclear localization and remains functional at 
the nucleus of metastatic prostate cancer cells. PLoS One. 
2013; 8:e57194.
36. Boora GK, Kanwar R, Kulkarni AA, Pleticha J, Ames M, 
Schroth G, Beutler AS, Banck MS. Exome-level comparison 
of primary well-differentiated neuroendocrine tumors and 
their cell lines. Cancer Genet. 2015; 208:374–81.
37. Vandamme T, Peeters M, Dogan F, Pauwels P, Van Assche E, 
Beyens M, Mortier G, Vandeweyer G, de Herder W, Van 
Camp G, Hofland LJ, Op de Beeck K. Whole-exome 
characterization of pancreatic neuroendocrine tumor cell lines 
BON-1 and QGP-1. J Mol Endocrinol. 2015; 54:137–47.
38. Modlin IM, Oberg K, Chung DC, Jensen RT, de 
Herder WW, Thakker RV, Caplin M, Delle Fave G, 
Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G 
Oncotarget16www.impactjournals.com/oncotarget
et al. Gastroenteropancreatic neuroendocrine tumours. 
Lancet Oncol. 2008; 9:61–72.
39. Ellis LM, Samuel S, Sceusi E. Varying opinions on the 
authenticity of a human midgut carcinoid cell line--letter. 
Clin Cancer Res. 2010; 16:5365–6.
40. Roccaro AM, Mishima Y, Sacco A, Moschetta M, Tai YT, 
Shi J, Zhang Y, Reagan MR, Huynh D, Kawano Y, Sahin I, 
Chiarini M, Manier S et al. CXCR4 Regulates Extra-
Medullary Myeloma through Epithelial-Mesenchymal-
Transition-like Transcriptional Activation. Cell Rep. 2015; 
12:622–35.
41. Van Buren G 2nd, Rashid A, Yang AD, Abdalla EK, Gray MJ, 
Liu W, Somcio R, Fan F, Camp ER, Yao JC, Ellis LM. 
The development and characterization of a human midgut 
carcinoid cell line. Clin Cancer Res. 2007; 13:4704–4712.
42. Frassanito MA, Silvestris F, Silvestris N, Cafforio P, 
Camarda G, Iodice G, Dammacco F. Fas/Fas ligand 
(FasL)-deregulated apoptosis and IL-6 insensitivity in 
highly malignant myeloma cells. Clin Exp Immunol. 1998; 
114:179–188.
43. Tucci M, Ciavarella S, Strippoli S, Brunetti O, Dammacco F, 
Silvestris F. Immature dendritic cells from patients with 
multiple myeloma are prone to osteoclast differentiation in 
vitro. Exp Hematol. 2011; 39:773–783.
44. Cives M, Ciavarella S, Rizzo FM, De Matteo M, 
Dammacco F, Silvestris F. Bendamustine overcomes 
resistance to melphalan in myeloma cell lines by inducing 
cell death through mitotic catastrophe. Cell Signal. 2013; 
25: 1108–1117.
45. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by 
the comparative C(T) method. Nat Protoc. 2008; 3:1101–1108.
46. Tucci M, De Palma R, Lombardi L, Rodolico G, Berrino L, 
Dammacco F, Silvestris F. beta(3) Integrin subunit mediates 
the bone-resorbing function exerted by cultured myeloma 
plasma cells. Cancer Res. 2009; 69:6738–46.
